Cardiac Arrhythmia and Conduction Disorders DRG Reimbursement

Summary & Overview

Cardiac Arrhythmia and Conduction Disorders with CC: Inpatient Reimbursement Overview

DRG 309 addresses inpatient admissions for cardiac arrhythmia and conduction disorders when a Complication or Comorbidity is present, encompassing symptomatic rhythm disturbances and conduction system disease requiring inpatient care. This Diagnosis-Related Group matters for inpatient reimbursement because the Complication or Comorbidity designation increases relative payment to account for higher resource utilization and clinical complexity during the hospital stay.

Cardiac Arrhythmia and Conduction Disorders with CCDRG Cardiac Arrhythmia and Conduction Disorders with CCDRG 309Diagnosis-Related GroupInpatient ReimbursementMedicareCardiologyCardiac ElectrophysiologyHospital CodingClinical Documentation

DRG 309 Overview

DRG 309 covers hospital stays for patients treated for cardiac arrhythmia and conduction disorders when a Complication or Comorbidity is present. Typical cases include symptomatic atrial or ventricular arrhythmias, conduction blocks, and related procedures or monitoring required during the admission. This Diagnosis-Related Group matters for Medicare payment because the presence of a Complication or Comorbidity elevates reimbursement relative to non-Complication or Comorbidity cohorts, reflecting increased resource use and clinical complexity. Accurate clinical documentation and coding of the arrhythmia and any associated Complication or Comorbidity directly influence payment assignment and hospital case mix.

National Payment Rates

Across payers, negotiated rates for this DRG range from about $7K (10th percentile for Aetna) up to $28K (maximum reported for Anthem), with mean payer benchmarks clustered between $7.5K and $12K. The widest spread between reported payer maxima and minima appears with Anthem (min $390 to max $28K). See the table and chart below for full percentile and payer details.

Mean Rates by Payer — National — DRG 309

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($7.0k), average submitted covered charges ($34.1k), average Medicare payment amount ($5.1k), and total discharges (65.2k).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s DRG 309 mean rates span from 11K to 18K across payers, reflecting a relatively narrow state range. Cigna sits at the high end (mean 18K) while Anthem and Blue Cross Blue Shield are clustered at the low end (mean 11K). This concentration contrasts with broader national dispersion where medians and means vary more widely. See the table and chart below for payer-level detail.

Key Insights for Alaska

Cigna is the highest paying payer in Alaska with a mean of 18K, while both Anthem and Blue Cross Blue Shield are the lowest at 11K.
The Alaska payer range (11K–18K) is compressed relative to national variability, with Cigna notably above the local cluster and exceeding typical national medians for some payers.

Clinical Trials

Trials of acute rhythm-control and stabilization strategies in hospitalized patients presenting with symptomatic arrhythmias or conduction block: these studies evaluate short-term interventions such as intravenous antiarrhythmic protocols, emergency external or temporary pacing algorithms, and protocolized electrolyte/catecholamine management in adults admitted for atrial fibrillation with rapid ventricular response, ventricular tachycardia, or high-grade AV block. The patient population is the inpatient cohort with hemodynamic compromise or significant symptoms requiring urgent management; outcomes include time to rhythm control, need for escalation to device therapy, in-hospital complications, and length of stay. This research is relevant to providers and payers because it targets interventions that can reduce immediate morbidity, prevent ICU transfer, and shorten hospitalization—key drivers of inpatient costs and DRG resource use.
Comparative effectiveness studies of invasive versus conservative management pathways for conduction disorders and recurrent arrhythmias in patients with comorbid cardiac disease: these investigations compare strategies such as expedited permanent pacemaker/ICD implantation versus extended medical optimization and outpatient follow-up for patients who have arrhythmia-related admissions with concurrent heart failure or ischemic heart disease. The population typically includes older adults with multiple comorbidities where the decision between procedural intervention during the index admission versus staged or noninvasive approaches is uncertain; endpoints measure readmission rates, procedure-related complications, functional status, and total 30–90 day costs. Payers and hospital decision-makers value this evidence because it informs resource-intensive choices that affect procedure utilization, readmissions, and bundled payment performance for DRG 309 patients.
Post-discharge outcomes and transitional care trials focused on secondary prevention, anticoagulation management, and remote monitoring: these studies evaluate structured discharge pathways, anticoagulation initiation and monitoring protocols for atrial arrhythmias, and use of ambulatory rhythm monitoring or telehealth follow-up to detect recurrence and prevent readmission in patients discharged after an arrhythmia or conduction disorder admission. The target population is patients recently discharged from the hospital with new or recurrent atrial fibrillation, flutter, or conduction device implantation, assessing outcomes such as 30- and 90-day readmission, stroke prevention metrics, adherence, and patient-reported quality of life. This area is important to providers and payers because effective transitional care can reduce preventable readmissions, improve guideline-concordant secondary prevention, and lower downstream costs associated with thromboembolic events and recurrent hospital care.

Related Codes

304-HYPERTENSION-WITH-MCC

Hypertension with Major Complication or Comorbidity: Inpatient Reimbursement Overview

254-OTHER-VASCULAR-PROCEDURES-WITHOUT-CC-MCC

Other Vascular Procedures without CC/MCC: Inpatient Reimbursement Overview

314-OTHER-CIRCULATORY-SYSTEM-DIAGNOSES-WITH-MCC

Other Circulatory System Diagnoses with MCC: Inpatient Reimbursement Overview

277-CARDIAC-DEFIBRILLATOR-IMPLANT-WITHOUT-MCC

Cardiac Defibrillator Implant without MCC: Inpatient Reimbursement Overview

307-CARDIAC-CONGENITAL-AND-VALVULAR-DISORDERS-WITHOUT-MCC

Cardiac Congenital and Valvular Disorders without MCC: Inpatient Reimbursement Overview

233-CORONARY-BYPASS-WITH-CARDIAC-CATHETERIZATION-OR-OPEN-ABLATION-WITH-MCC

Coronary Bypass with Cardiac Catheterization or Open Ablation with MCC: Inpatient Reimbursement Overview

243-PERMANENT-CARDIAC-PACEMAKER-IMPLANT-WITH-CC

Permanent Cardiac Pacemaker Implant with CC: Inpatient Reimbursement Overview

300-PERIPHERAL-VASCULAR-DISORDERS-WITH-CC

Peripheral Vascular Disorders with CC: Inpatient Reimbursement Overview

215-OTHER-HEART-ASSIST-SYSTEM-IMPLANT

Other Heart Assist System Implant: Inpatient Reimbursement Overview

251-PERCUTANEOUS-CARDIOVASCULAR-PROCEDURES-WITHOUT-INTRALUMINAL-DEVICE-WITHOUT-MCC

Percutaneous Cardiovascular Procedures without Intraluminal Device without MCC: Inpatient Reimbursement Overview

Showing 1–10 of 100

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$7K	$34K	$5.1K	65K

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Mean Rates by Payer — Alaska — DRG 309

Key Insights for Alaska

Cigna is the highest paying payer in Alaska with a mean of 18K, while both Anthem and Blue Cross Blue Shield are the lowest at 11K.
The Alaska payer range (11K–18K) is compressed relative to national variability, with Cigna notably above the local cluster and exceeding typical national medians for some payers.

Clinical Trials

Trials of acute rhythm-control and stabilization strategies in hospitalized patients presenting with symptomatic arrhythmias or conduction block: these studies evaluate short-term interventions such as intravenous antiarrhythmic protocols, emergency external or temporary pacing algorithms, and protocolized electrolyte/catecholamine management in adults admitted for atrial fibrillation with rapid ventricular response, ventricular tachycardia, or high-grade AV block. The patient population is the inpatient cohort with hemodynamic compromise or significant symptoms requiring urgent management; outcomes include time to rhythm control, need for escalation to device therapy, in-hospital complications, and length of stay. This research is relevant to providers and payers because it targets interventions that can reduce immediate morbidity, prevent ICU transfer, and shorten hospitalization—key drivers of inpatient costs and DRG resource use.
Comparative effectiveness studies of invasive versus conservative management pathways for conduction disorders and recurrent arrhythmias in patients with comorbid cardiac disease: these investigations compare strategies such as expedited permanent pacemaker/ICD implantation versus extended medical optimization and outpatient follow-up for patients who have arrhythmia-related admissions with concurrent heart failure or ischemic heart disease. The population typically includes older adults with multiple comorbidities where the decision between procedural intervention during the index admission versus staged or noninvasive approaches is uncertain; endpoints measure readmission rates, procedure-related complications, functional status, and total 30–90 day costs. Payers and hospital decision-makers value this evidence because it informs resource-intensive choices that affect procedure utilization, readmissions, and bundled payment performance for DRG 309 patients.
Post-discharge outcomes and transitional care trials focused on secondary prevention, anticoagulation management, and remote monitoring: these studies evaluate structured discharge pathways, anticoagulation initiation and monitoring protocols for atrial arrhythmias, and use of ambulatory rhythm monitoring or telehealth follow-up to detect recurrence and prevent readmission in patients discharged after an arrhythmia or conduction disorder admission. The target population is patients recently discharged from the hospital with new or recurrent atrial fibrillation, flutter, or conduction device implantation, assessing outcomes such as 30- and 90-day readmission, stroke prevention metrics, adherence, and patient-reported quality of life. This area is important to providers and payers because effective transitional care can reduce preventable readmissions, improve guideline-concordant secondary prevention, and lower downstream costs associated with thromboembolic events and recurrent hospital care.